动物用药品原料药（依动物类型、产品类型、化合物类型、给药途径和来源）－2025-2032 年全球预测

预计到 2032 年，动物用药品原料药市场将成长至 360.8 亿美元，复合年增长率为 8.47%。

动物用药品原料药领域的综合框架强调了科学创新、监管现实和供应链复杂性，以形成战略选择

动物用药品的原料药药物成分 (API) 处于科学创新、监管监督和复杂的全球供应链的交汇点。本介绍概述了再形成该行业的关键力量：对高价值生技药品和多肽的需求不断增长、对抗菌药物管理的审查日益严格、给药途径偏好的不断演变，以及对采购永续性和可追溯性的日益重视。这些动态与原材料供应和物流的持续压力相伴而生，要求更细緻的产品开发和采购方法。

加速的技术创新正在推动行业化合物类型和递送系统的多样化。生物製药拓展了治疗的可能性，但需要在生产能力和低温运输物流进行大量投资。同时，小分子对于许多关键适应症仍然至关重要，而胜肽则提供了一条将特异性与改进的生产过程相结合的中间路径。法律规范不断适应这些变化，强调品质源自于设计、药物安全检测，并明确要求提供支持目标物种安全性的数据。因此，组织必须在开发早期就将其科学策略与合规蓝图结合，以避免下游延迟。

供应链考量同样是策略规划的核心。原料药的采购状况——无论是发酵衍生、天然萃取物或合成——都会影响原料短缺、地缘政治事件和关税变化所带来的风险暴露。同时，给药途径的创新也会影响製剂的复杂性和生产足迹。吸入、口服、肠外和局部给药各自反映不同的技术和商业性权衡。总而言之，这些主题为製造商、受託製造厂商、经销商以及为下一波产品推出做准备的动物用药品公司带来了机会和风险。

分析重塑动物用药品原料药动态和製造方法的科学、运作和商业性融合力量。

动物用药品原料药领域正在经历一系列变革时期正在改变竞争边界和投资重点。首先，治疗重点正转向针对特定物种的标靶介入。生技药品和多肽正在将治疗范围扩大到伴侣动物和高价值牲畜，而抗生素管理计画正在推动配方改进和非抗生素替代品的开发。这种科学转变需要新的製造能力、增强的低温运输物流以及研发和製造团队之间更紧密的合作。

其次，为了应对持续的供应链中断和不断变化的贸易政策，市场参与企业正在重新评估其采购和製造足迹。这种重新调整体现在更注重区域供应链的弹性，更多地利用契约製造来灵活调整生产能力，以及对关键中间体进行策略性储备。同时，永续性正从合规性考量转变为竞争优势。企业正在投资更绿色的化学製程、减少溶剂使用和废弃物最小化策略，以减少对环境的影响并降低监管风险。

第三，数位化和数据主导的品质体係正在重塑整个研发和製造流程的营运效率。企业越来越多地采用製程分析技术、预测性维护和数位化批次记录，以加快研发週期并增强可追溯性。监管机构也青睐能够证明品质一致性的数位证据，从而形成良性循环，提高资料保真度可以减少检查摩擦并加快核准。最后，我们看到各种合作模式层出不穷——从与学术中心的策略联盟到跨产业联盟——各组织都在寻求共用担风险、挖掘专业技能，并加速将新型疗法转化为商业产品。这些转变共同塑造了一个更模组化、更具弹性、更创新驱动的产业架构。

检验最近的关税措施将如何显着改变动物用药品原料药链中的采购经济、供应商选择和合规负担

近期的关税措施和贸易政策调整，增加了动物用药品生物製药原料药采购、生产和分销相关人员的复杂性。关税不仅透过对成品原料药和中间体征收直接进口关税来影响成本结构，还透过改变生物製剂和多肽药物生产所需的原材料、专用试剂和资本设备的采购成本来影响成本结构。为此，企业正在审查供应商合同，评估近岸外包方案，并重新评估总到岸成本模型，以保持利润率和供应的连续性。

关税不仅影响成本，还会推动整个价值链的行为改变。製造商可能会优先考虑国内或区域供应商的关键投入，从而可能加速对本地产能或委託製造伙伴关係关係的投资。相反，一些公司可能会选择承担额外的关税，以维持与提供卓越品质或计划能力的可信赖供应商的关係。对于监管团队而言，关税驱动的供应商变更通常需要补充检验工作和文件更新，以保持跨司法管辖区的合规性，从而增加专案时间表和管理负担。

从策略上讲，最具韧性的公司正在采用多层次的方法来应对关税风险，将多元化采购、包含明确升级条款的长期供应合约以及库存优化相结合，以缓衝短期衝击。对供应商网路进行情境规划和压力测试可以揭示其脆弱性，并指导采取积极的缓解措施，例如对关键中间体进行双重采购以及投资替代合成路线。此外，投资于供应链透明度和关税影响分析的组织能够更好地向商业伙伴和监管机构传达价格调整和风险缓解策略，使他们在政策不确定性的情况下也能保持信任和市场进入。

将动物种类、治疗类别、化合物类别、给药途径和原产国与开发和供应链要求联繫起来的详细細項分析

细分洞察揭示了科学创新、监管重点和商业性需求的交汇，从而在动物用药品原料药领域创造了差异化的机会。根据动物种类，水产养殖、伴侣动物、牲畜和家禽的市场需求驱动因素和产品开发重点有显着差异。伴侣动物通常引领尖端生技药品的应用，而水产养殖则需要能够耐受水生环境的製剂。按产品类型划分，治疗产品组合涵盖抗发炎药物、抗生素、抗寄生虫药、荷尔蒙和疫苗，每个类别都面临不同的製造和监管挑战。疫苗和抗寄生虫药物通常需要强大的低温运输和稳定性策略，而小分子抗生素则强调经济高效的合成路线和管理方案。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 长效注射药物越来越多地被采用来改善牲畜疾病管理
• 加强法规以减少动物粪便和周围生态系统中的兽用 AP 残留
• 增加对新型兽医免疫疗法和疫苗重组蛋白 API 的投资
• 动物用药品公司与契约製造製造商建立策略联盟以扩大 API 生产能力
• 连续流合成技术在经济高效、高纯度兽药 API 生产的进展
• 兽药原料药采购中永续植物来源萃取方法的新兴趋势
• 扩大拉丁美洲动物用药品原料药(API) 生产设施，以满足该地区日益增长的蛋白质需求
• 实施数位双胞胎技术优化兽药API程式参数并减少批次错误

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章动物用药品原料药（依动物类型）

• 水产养殖
• 伴侣动物
• 家畜
• 家禽

第九章动物用药品原料药（依产品类型）

• 抗发炎药物
• 抗生素
• 抗寄生虫药
• 荷尔蒙
• 疫苗

第 10 章动物用药品原料药（依化合物类型）

• 生物製药
• 胜肽
• 小分子

第十一章动物用药品原料药依管理途径

• 吸入
  • 气雾剂
  • 干粉
  • 喷雾器
• 口服
  • Bolus
  • 颗粒
  • 粉末
  • 药片
• 肠外
  • 肌肉注射
  • 静脉
  • 皮下
• 外用
  • 皮肤科
  • 眼科
  • 耳科

第十二章动物用药品原料药市场（依来源）

• 发酵衍生
• 天然萃取物
• 合成

第十三章动物用药品原料药（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章动物用药品原料药：依类别

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章动物用药品原料药（按国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Virbac SA
  • Ceva Sante Animale SA
  • Vetoquinol SA
  • Phibro Animal Health Corporation
  • Dechra Pharmaceuticals PLC
  • Norbrook Laboratories Limited

The Animal Health Active Pharmaceutical Ingredients Market is projected to grow by USD 36.08 billion at a CAGR of 8.47% by 2032.

Comprehensive framing of the animal health API arena emphasizing scientific innovation, regulatory realities, and supply chain complexity shaping strategic choices

The active pharmaceutical ingredients (APIs) that underpin animal health therapeutics are at the intersection of scientific innovation, regulatory oversight, and complex global supply chains. This introduction sets the stage by outlining the principal drivers reshaping the sector: rising demand for higher-value biologics and peptides, heightened scrutiny around antimicrobial stewardship, evolving route-of-administration preferences, and the increasing emphasis on sustainability and traceability in sourcing. These dynamics are occurring alongside persistent pressures on raw material availability and logistics, which together require a more nuanced approach to product development and procurement.

As innovation accelerates, the industry is witnessing a diversification of compound types and delivery systems. Biologic APIs are expanding therapeutic possibilities but also demand significant investments in manufacturing capability and cold-chain logistics. At the same time, small molecules remain essential for many core indications, and peptides offer a middle path that combines specificity with manufacturing improvements. Regulatory frameworks continue to adapt to these shifts, emphasizing quality-by-design, pharmacovigilance, and explicit requirements for data supporting safety in target species. Consequently, organizations must align scientific strategy with compliance roadmaps early in development to avoid downstream delays.

Supply chain considerations are equally central to strategic planning. The sourcing profile of APIs-whether fermentation derived, natural extracted, or synthetic-affects risk exposure to raw material shortages, geopolitical events, and tariff changes. In parallel, route-of-administration innovation influences formulation complexity and manufacturing footprints; inhalation, oral, parenteral, and topical modalities each present distinct technical and commercial trade-offs. Taken together, these themes create both opportunities and risks for manufacturers, contract development and manufacturing organizations, distributors, and veterinary pharmaceutical companies that are preparing for the next wave of product introductions.

Analysis of converging scientific, operational, and commercial forces that are remapping competitive dynamics and manufacturing approaches in animal health APIs

The animal health API landscape is undergoing a series of transformative shifts that are altering competitive boundaries and investment priorities. First, the therapeutic focus is gravitating toward targeted and species-specific interventions: biologics and peptides are expanding therapeutic reach for companion animals and high-value livestock applications, while antibiotic stewardship programs are driving reformulation and the development of non-antimicrobial alternatives. These scientific shifts necessitate new manufacturing capabilities, stronger cold-chain logistics, and closer collaboration between R&D and manufacturing teams.

Second, market participants are reassessing sourcing and manufacturing footprints in response to persistent supply chain disruptions and changing trade policies. This recalibration manifests as greater interest in regional supply network resilience, expanded use of contract manufacturing to flex capacity, and strategic stockpiling for critical intermediates. Simultaneously, sustainability has moved from a compliance checkbox to a competitive differentiator; companies are investing in greener chemistries, reduced solvent use, and waste minimization strategies that lower environmental impact while mitigating regulatory risk.

Third, digitalization and data-driven quality systems are reshaping operational effectiveness across development and manufacture. Companies increasingly deploy process analytical technology, predictive maintenance, and digital batch records to accelerate development cycles and enhance traceability. Regulatory authorities are also receptive to digital evidence demonstrating consistent quality, which creates a virtuous cycle: improved data fidelity reduces inspection friction and supports accelerated approvals. Finally, collaborative models-ranging from strategic alliances with academic centers to cross-industry consortia-are proliferating as organizations seek to share risk, access niche expertise, and accelerate the translation of novel modalities into commercial products. Collectively, these shifts are driving a more modular, resilient, and innovation-oriented industry architecture.

Examination of how recent tariff measures materially alter sourcing economics, supplier selection, and compliance burdens across the animal health API value chain

Recent tariff actions and trade policy adjustments have introduced an additional layer of complexity for actors engaged in the procurement, manufacture, and distribution of animal health APIs. Tariffs influence cost structures not only through direct import duties on finished APIs and intermediates but also by altering the economics of raw material sourcing, specialized reagents, and capital equipment required for biologic and peptide production. In response, organizations are revisiting supplier agreements, assessing nearshoring options, and reevaluating total landed cost models to preserve margins and continuity of supply.

Beyond cost implications, tariffs create behavioral shifts across the value chain. Manufacturers may prioritize domestic or regional suppliers for critical inputs, which can accelerate investment in local capacity and contract manufacturing partnerships. Conversely, some firms will choose to absorb additional duties to maintain relationships with trusted suppliers that offer superior quality or unique capabilities. For regulatory affairs teams, tariff-driven supplier changes often necessitate supplemental validation work and documentation updates to maintain compliance across jurisdictions, thereby increasing project timelines and administrative burden.

Strategically, the most resilient organizations adopt a layered approach to tariff exposure: they combine diversified sourcing, longer-term supply agreements with clear escalation clauses, and inventory optimization to smooth short-term shocks. Scenario planning and stress-testing of supplier networks reveal vulnerabilities and guide proactive mitigation measures, such as dual sourcing and investment in alternative synthesis routes for key intermediates. Moreover, organizations that invest in supply chain transparency and tariff impact analytics are better positioned to communicate price adjustments and risk mitigation strategies to commercial partners and regulators, preserving trust and market access despite policy uncertainty.

In-depth segmentation analysis linking animal type, therapeutic category, compound class, administration routes, and source origins to development and supply chain imperatives

Segmentation insights reveal where scientific innovation, regulatory focus, and commercial demand intersect to create differentiated opportunities across the animal health API landscape. Based on animal type, the market's demand drivers and product development priorities diverge significantly between aquaculture, companion animal, livestock, and poultry, with companion animals often leading adoption of cutting-edge biologics and aquaculture requiring formulations tolerant of aquatic environments. Based on product type, the therapeutic portfolio spans anti-inflammatories, antibiotics, antiparasitics, hormones, and vaccines, and each category presents distinct manufacturing and regulatory challenges; vaccines and antiparasitics typically demand robust cold-chain and stability strategies, whereas small-molecule antibiotics emphasize cost-effective synthetic routes and stewardship programs.

Based on compound type, biologics, peptides, and small molecules create three clear manufacturing pathways: biologics require cell-culture expertise and stringent aseptic environments; peptides benefit from advances in solid-phase synthesis and purification technologies; and small molecules continue to leverage mature chemical synthesis networks that prioritize yield and impurity control. Based on route of administration, inhalation, oral, parenteral, and topical routes impose different formulation constraints and delivery system investments. The inhalation modality further subdivides into aerosol, dry powder, and nebulization formats each with unique device and characterization demands, while the oral route includes bolus, granules, powder, and tablet formats that influence animal dosing behavior and palatability considerations. Parenteral routes-intramuscular, intravenous, and subcutaneous-demand sterility assurance and compatibility testing, and topical applications-dermatological, ophthalmic, and otic-require focused local-tolerability and stability studies.

Finally, based on source, fermentation derived, natural extracted, and synthetic origins affect supplier ecosystems and risk profiles: fermentation derived APIs can tie manufacturers to biotech supply chains and fermentation capacity constraints, natural extracts present variability and sustainability questions, and synthetic APIs lean on chemical precursor availability and process innovation. Understanding these segmentation layers in aggregate enables targeted investment, regulatory planning, and commercialization strategies that are appropriate for specific therapeutic targets and end-user contexts.

Strategic regional assessment that contrasts regulatory sophistication, manufacturing capabilities, and commercialization dynamics across global regions to inform localization

Regional dynamics play a pivotal role in shaping sourcing strategies, regulatory expectations, and commercial adoption across the animal health API sector. The Americas present a mature regulatory environment and advanced manufacturing capabilities, with strong demand for high-value therapeutics in companion and specialty livestock applications. Market participants in this region increasingly focus on biologics and peptide innovation, supported by robust clinical trial infrastructures and established cold-chain logistics, while also navigating supply chain security and tariff-driven cost considerations.

Europe, Middle East & Africa combines diverse regulatory regimes and market maturities, ranging from highly harmonized European standards to emerging regulatory frameworks in parts of the Middle East and Africa. This heterogeneity creates both challenges and opportunities: companies can leverage Europe's stringent quality expectations to validate premium products, while regionally tailored strategies are necessary to address affordability constraints and distribution complexities across varied geographies. Sustainability and antimicrobial stewardship are particularly prominent themes in this region, influencing both regulation and purchasing decisions.

Asia-Pacific is characterized by rapid demand growth, developing manufacturing capabilities, and a complex patchwork of regulatory pathways. The region is a critical node for chemical and biologic production, and many organizations rely on Asia-Pacific suppliers for key intermediates and API manufacturing. At the same time, rising domestic R&D investments and increasing regulatory sophistication are creating new centers of innovation and localized product development. Across all regions, companies that align manufacturing, regulatory, and commercial strategies to regional characteristics gain competitive advantage and reduce market-entry friction.

Evaluation of how corporate strategies, capability specialization, and collaborative models are reshaping competitive advantages and partnership patterns in the API ecosystem

Company-level dynamics are being reshaped by a combination of strategic investment, capability specialization, and collaborative linkages across the value chain. Leading firms and specialized contract development and manufacturing organizations are differentiating through focused capability stacks-such as biologics process development, peptide synthesis scale-up, or complex inhalation device integration-to serve niche clinical and commercial needs. These capability clusters create higher barriers to entry for commodity players while opening partnership opportunities for firms that lack in-house expertise.

At the same time, mergers, strategic alliances, and technology licensing are common mechanisms for companies to accelerate capability acquisition and market entry without the full burden of capital investment. Such arrangements frequently involve cross-border collaboration and create implications for intellectual property management, regulatory filings, and cross-jurisdictional quality systems. Talent and technical know-how remain limiting factors in advanced modalities; companies that invest in workforce development and knowledge transfer programs secure a reproducible advantage in complex API production.

Finally, firms that proactively embed sustainability, traceability, and digital quality systems into their operations increase their appeal to large purchasers and regulatory stakeholders. Demonstrable commitments to greener chemistries, lower carbon footprints, and transparent sourcing strengthen commercial positioning and can accelerate approvals in markets prioritizing environmental stewardship. Collectively, these company-level moves determine who can deliver high-complexity APIs reliably and cost-effectively into an increasingly demanding market.

Actionable playbook for executives to enhance resilience, accelerate biologics and peptide capabilities, and optimize sourcing and regulatory engagement in animal health APIs

Industry leaders should pursue a pragmatic combination of strategic investments and operational adjustments to convert risk into opportunity. First, diversify supplier networks and build regional redundancy for critical intermediates and specialized reagents to reduce exposure to single points of failure and tariff volatility. Investing in dual sourcing and nearshoring for priority inputs supports continuity while enabling faster regulatory response when supplier changes are required. Second, allocate capital toward biologics and peptide manufacturing capabilities where scientific and commercial signals indicate durable demand; paired with strategic partnerships, this reduces time-to-market and leverages external expertise without overextending internal resources.

Third, prioritize route-of-administration innovation that aligns with end-user preferences and administration feasibility; for companion animals, palatability and easy-to-administer formats are often decisive, whereas for livestock and poultry, dosing efficiency and cost per treatment dominate decisions. Fourth, enhance regulatory engagement early and often: share development plans with regulatory bodies, pursue parallel consultations across jurisdictions when feasible, and standardize documentation to reduce approval timelines and inspection risk. Fifth, embed sustainability in procurement and process design through greener chemistry choices, waste reduction programs, and transparent sourcing protocols that can be evidenced to buyers and regulators.

Finally, operationalize data and digital solutions to improve traceability, predictive maintenance, and quality assurance. Implementing process analytical technologies and robust batch record systems reduces variability and supports faster scale-up. Scenario planning and tariff-impact modeling should be integrated into commercial and procurement decision processes so that price adjustments and sourcing shifts can be made proactively and communicated clearly to stakeholders. Taken together, these steps help create a resilient, innovation-ready organization capable of navigating emerging policy and market challenges.

Transparent research methodology combining primary interviews, secondary literature, and triangulated evidence to produce robust, actionable industry insights

The research underpinning this analysis combines primary qualitative insights with comprehensive secondary data synthesis to ensure robustness and relevance. Primary inputs include structured interviews with industry stakeholders such as formulation scientists, manufacturing leaders, procurement professionals, veterinary clinical experts, and regulatory affairs specialists. These conversations provided frontline perspectives on supply chain constraints, technological adoption, and unmet therapeutic needs across different animal types and administration routes. Where possible, cross-validation with multiple stakeholder groups was used to reconcile differing views and identify persistent patterns.

Secondary research encompassed authoritative scientific literature, regulatory guidance documents, patent filings, and public disclosures of manufacturing investments and partnerships. Information from trade publications and conference proceedings supplemented these sources to capture recent product launches, technology demonstrations, and collaborative announcements. Data triangulation ensured that conclusions were not reliant on any single source and allowed for the identification of convergent trends across independent inputs.

Methodological rigor included clear inclusion criteria for sources, transparent documentation of interview protocols, and quality checks on interpretive analysis. Limitations are acknowledged: rapidly evolving policies and commercial arrangements may change the competitive landscape between updates, and access constraints limit the granularity of some proprietary supply agreements. To mitigate these factors, the methodology emphasizes scenario-based insights and identifies leading indicators that stakeholders can monitor to update their strategic assessments in real time.

Concise synthesis of the strategic imperatives and operational priorities that will determine success in the evolving animal health API market

The cumulative picture is one of an industry in transition, where scientific advancements, regulatory evolution, and supply chain realities intersect to redefine strategic priorities. Biologics and peptides are reshaping therapeutic possibilities, whereas small molecules retain a central role in core indications. Route-of-administration choices and source origins materially influence manufacturing complexity, regulatory requirements, and commercial uptake, and they must be considered as integral elements of product strategy rather than afterthoughts.

Regional dynamics and tariff environments further complicate planning, making supply chain transparency and diversified sourcing essential components of resilience. Companies that invest in specialized capabilities, embrace collaborative models for capacity and knowledge sharing, and embed sustainability and digital quality systems into their operations will be best positioned to capture the upside of innovation while controlling downside risk. Ultimately, a disciplined, multidimensional approach that links R&D, manufacturing, procurement, regulatory, and commercial teams yields the strongest foundation for long-term success in the animal health API sector.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Growing adoption of long-acting injectable API formulations to improve livestock disease management
• 5.2. Rising regulatory focus on reducing veterinary API residues in animal waste and surrounding ecosystems
• 5.3. Increased investments in recombinant protein APIs for novel veterinary immunotherapies and vaccines
• 5.4. Strategic collaborations between animal health companies and contract manufacturers to scale API production capacity
• 5.5. Advancements in continuous flow synthesis for cost-effective and high-purity veterinary API manufacturing
• 5.6. Emerging trend of sustainable plant-based extraction methods for veterinary API raw material sourcing
• 5.7. Expansion of animal health API production facilities in Latin America to meet growing regional protein demand
• 5.8. Implementation of digital twin technology to optimize veterinary API process parameters and reduce batch failures

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Health Active Pharmaceutical Ingredients Market, by Animal Type

• 8.1. Aquaculture
• 8.2. Companion Animal
• 8.3. Livestock
• 8.4. Poultry

9. Animal Health Active Pharmaceutical Ingredients Market, by Product Type

• 9.1. Anti Inflammatories
• 9.2. Antibiotics
• 9.3. Antiparasitics
• 9.4. Hormones
• 9.5. Vaccines

10. Animal Health Active Pharmaceutical Ingredients Market, by Compound Type

• 10.1. Biologic
• 10.2. Peptide
• 10.3. Small Molecule

11. Animal Health Active Pharmaceutical Ingredients Market, by Route Of Administration

• 11.1. Inhalation
  • 11.1.1. Aerosol
  • 11.1.2. Dry Powder
  • 11.1.3. Nebulization
• 11.2. Oral
  • 11.2.1. Bolus
  • 11.2.2. Granules
  • 11.2.3. Powder
  • 11.2.4. Tablet
• 11.3. Parenteral
  • 11.3.1. Intramuscular
  • 11.3.2. Intravenous
  • 11.3.3. Subcutaneous
• 11.4. Topical
  • 11.4.1. Dermatological
  • 11.4.2. Ophthalmic
  • 11.4.3. Otic

12. Animal Health Active Pharmaceutical Ingredients Market, by Source

• 12.1. Fermentation Derived
• 12.2. Natural Extracted
• 12.3. Synthetic

13. Animal Health Active Pharmaceutical Ingredients Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Animal Health Active Pharmaceutical Ingredients Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Animal Health Active Pharmaceutical Ingredients Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Zoetis Inc.
  • 16.3.2. Elanco Animal Health Incorporated
  • 16.3.3. Merck & Co., Inc.
  • 16.3.4. Boehringer Ingelheim International GmbH
  • 16.3.5. Virbac SA
  • 16.3.6. Ceva Sante Animale S.A.
  • 16.3.7. Vetoquinol S.A.
  • 16.3.8. Phibro Animal Health Corporation
  • 16.3.9. Dechra Pharmaceuticals PLC
  • 16.3.10. Norbrook Laboratories Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AEROSOL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AEROSOL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AEROSOL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AEROSOL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DRY POWDER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DRY POWDER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DRY POWDER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DRY POWDER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DRY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DRY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NEBULIZATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NEBULIZATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NEBULIZATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NEBULIZATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NEBULIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NEBULIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BOLUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BOLUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BOLUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BOLUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BOLUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BOLUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GRANULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GRANULES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GRANULES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GRANULES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GRANULES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GRANULES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DERMATOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DERMATOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DERMATOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DERMATOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DERMATOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DERMATOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OPHTHALMIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OTIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OTIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OTIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OTIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OTIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY OTIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 221. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 222. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 223. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2024 (USD MILLION)
• TABLE 224. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2025-2032 (USD MILLION)
• TABLE 225. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 226. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 227. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 228. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 229. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 230. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 231. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 232. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
• TABLE 233. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 234. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 235. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
• TABLE 236. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 240. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 242. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2024 (USD MILLION)
• TABLE 244. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2025-2032 (USD MILLION)
• TABLE 245. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 246. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
• TABLE 248. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
• TABLE 249. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 250. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 251. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 252. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
• TABLE 253. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 254. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 255. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
• TABLE 256. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 260. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL